Commitments and Contingencies - Narrative (Details) $ in Millions |
6 Months Ended |
|---|---|
|
Jun. 30, 2026
USD ($)
| |
| Agilis | |
| Other Commitments | |
| Development milestone payments which the entity is obligated to pay | $ 40.0 |
| Agilis | Minimum | |
| Other Commitments | |
| Product sales (as a percent) | 2.00% |
| Agilis | Maximum | |
| Other Commitments | |
| Development milestone payments which the entity is obligated to pay | $ 60.0 |
| Priority review voucher amount | 535.0 |
| Potential sales milestones | $ 150.0 |
| Product sales (as a percent) | 6.00% |
| BioElectron | |
| Other Commitments | |
| Remaining potential contingent milestone | $ 200.0 |
| BioElectron | Maximum | |
| Other Commitments | |
| Development milestone payments which the entity is obligated to pay | 200.0 |
| Emflaza/Kebilidi | Agilis | |
| Other Commitments | |
| Potential sales milestones | $ 50.0 |